Novel MBLs inhibitors screened from FDA-approved drug library restore the susceptibility of carbapenems to NDM-1-harbouring bacteria.

Yan GuoHongtao LiuMengge YangRui DingYawen GaoXiaodi NiuXuming DengJianfeng Wang Haihua Feng Jiazhang Qiu

Published in: British journal of pharmacology (2023)

Our observations indicated that dexrazoxane, embelin, CAN and NDGA are promising carbapenem adjuvants against MBLs-positive carbapenem resistant bacterial pathogens.

Keyphrases

klebsiella pneumoniae
gram negative
multidrug resistant
escherichia coli
acinetobacter baumannii
drug administration
drug resistant
antimicrobial resistance
emergency department